Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
Calgary, Alberta--(. - September 10, 2026) - Resverlogix Corp. TSX:RVX ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms relating to heart failure prevention by the Company's lead clinical candidate, apabetalone."One o…